These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

805 related articles for article (PubMed ID: 33999164)

  • 1. Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
    Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
    JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between African American Race and Clinical Outcomes in Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
    Deka R; Courtney PT; Parsons JK; Nelson TJ; Nalawade V; Luterstein E; Cherry DR; Simpson DR; Mundt AJ; Murphy JD; D'Amico AV; Kane CJ; Martinez ME; Rose BS
    JAMA; 2020 Nov; 324(17):1747-1754. PubMed ID: 33141207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.
    Schenk JM; Newcomb LF; Zheng Y; Faino AV; Zhu K; Nyame YA; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW
    J Urol; 2020 Apr; 203(4):727-733. PubMed ID: 31651227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.
    Yamoah K; Lee KM; Awasthi S; Alba PR; Perez C; Anglin-Foote TR; Robison B; Gao A; DuVall SL; Katsoulakis E; Wong YN; Markt SC; Rose BS; Burri R; Wang C; Aboiralor O; Fink AK; Nickols NG; Lynch JA; Garraway IP
    JAMA Netw Open; 2022 Jan; 5(1):e2144027. PubMed ID: 35040965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.
    Jayadevan R; Felker ER; Kwan L; Barsa DE; Zhang H; Sisk AE; Delfin M; Marks LS
    JAMA Netw Open; 2019 Sep; 2(9):e1911019. PubMed ID: 31509206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison by Race of Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 2004 to 2018.
    Parikh RB; Robinson KW; Chhatre S; Medvedeva E; Cashy JP; Veera S; Bauml JM; Fojo T; Navathe AS; Malkowicz SB; Mamtani R; Jayadevappa R
    JAMA Netw Open; 2020 Sep; 3(9):e2018318. PubMed ID: 32986109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.
    Moul JW; Sesterhenn IA; Connelly RR; Douglas T; Srivastava S; Mostofi FK; McLeod DG
    JAMA; 1995 Oct; 274(16):1277-81. PubMed ID: 7563532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. African-American men with low-risk prostate cancer treated with radical prostatectomy in an equal-access health care system: implications for active surveillance.
    Deka R; Parsons JK; Simpson DR; Riviere P; Nalawade V; Vitzthum LK; Kader AK; Kane CJ; Rock CS; Murphy JD; Rose BS
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):581-588. PubMed ID: 32327702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.
    Newcomb LF; Schenk JM; Zheng Y; Liu M; Zhu K; Brooks JD; Carroll PR; Dash A; de la Calle CM; Ellis WJ; Filson CP; Gleave ME; Liss MA; Martin F; McKenney JK; Morgan TM; Tretiakova MS; Wagner AA; Nelson PS; Lin DW
    JAMA; 2024 Jun; 331(24):2084-2093. PubMed ID: 38814624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
    Maggi M; Cowan JE; Fasulo V; Washington SL; Lonergan PE; Sciarra A; Nguyen HG; Carroll PR
    J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active surveillance for intermediate-risk prostate cancer in African American and non-Hispanic White men.
    Courtney PT; Deka R; Kotha NV; Cherry DR; Salans MA; Nelson TJ; Kumar A; Luterstein E; Yip AT; Nalawade V; Parsons JK; Kader AK; Stewart TF; Rose BS
    Cancer; 2021 Dec; 127(23):4403-4412. PubMed ID: 34347291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Racial Disparities in Active Surveillance for Prostate Cancer.
    Krishna S; Fan Y; Jarosek S; Adejoro O; Chamie K; Konety B
    J Urol; 2017 Feb; 197(2):342-349. PubMed ID: 27596691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy.
    Leapman MS; Freedland SJ; Aronson WJ; Kane CJ; Terris MK; Walker K; Amling CL; Carroll PR; Cooperberg MR
    J Urol; 2016 Nov; 196(5):1408-1414. PubMed ID: 27352635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone.
    Marar M; Long Q; Mamtani R; Narayan V; Vapiwala N; Parikh RB
    JAMA Netw Open; 2022 Jan; 5(1):e2142093. PubMed ID: 34985518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.
    Iremashvili V; Manoharan M; Lokeshwar SD; Rosenberg DL; Pan D; Soloway MS
    BJU Int; 2013 Mar; 111(3):396-403. PubMed ID: 22703025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Prostate-Specific Antigen Screening and Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White US Veterans.
    Sherer MV; Qiao EM; Kotha NV; Qian AS; Rose BS
    JAMA Oncol; 2022 Oct; 8(10):1471-1476. PubMed ID: 35925581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Access to Prostate-Specific Antigen Testing and Mortality Among Men With Prostate Cancer.
    Iyer HS; Stone BV; Roscoe C; Hsieh MC; Stroup AM; Wiggins CL; Schumacher FR; Gomez SL; Rebbeck TR; Trinh QD
    JAMA Netw Open; 2024 Jun; 7(6):e2414582. PubMed ID: 38833252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
    Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
    JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time.
    Ng MK; Van As N; Thomas K; Woode-Amissah R; Horwich A; Huddart R; Khoo V; Thompson A; Dearnaley D; Parker C
    BJU Int; 2009 Apr; 103(7):872-6. PubMed ID: 18990146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer.
    Tewari A; Horninger W; Badani KK; Hasan M; Coon S; Crawford ED; Gamito EJ; Wei J; Taub D; Montie J; Porter C; Divine GW; Bartsch G; Menon M
    BJU Int; 2005 Jul; 96(1):29-33. PubMed ID: 15963115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.